The role of urine IgG in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis

Background IgA nephropathy (IgAN), the most common glomerulonephritis in the world, is an important cause of end-stage renal disease (ESRD). It is necessary to explore new prognostic markers for predicting the activity and progress of IgAN. There are few studies on new prognostic markers in IgAN pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International urology and nephrology 2022-02, Vol.54 (2), p.323-330
Hauptverfasser: Xu, Xianqi, Huang, Xiaodan, Chen, Yizhen, Li, Jundu, Shen, Miaoying, Hou, Yuansheng, Lin, Xuefei, Lin, Qizhan, Liu, Xusheng, Bao, Kun, Wang, Lixin, Yang, Haifeng, Liu, Lichang, Zou, Chuan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background IgA nephropathy (IgAN), the most common glomerulonephritis in the world, is an important cause of end-stage renal disease (ESRD). It is necessary to explore new prognostic markers for predicting the activity and progress of IgAN. There are few studies on new prognostic markers in IgAN patients with high proportion of glomerulosclerosis. This study aims to explore the value of urine IgG in predicting the prognosis of IgAN patients. Methods The primary end point of this retrospective study was a composite event with a reduction in estimated glomerular filtration rate (eGFR) of  ≥ 50% or ESRD or death. This study assessed the association between urinary IgG and clinicopathological parameters, as well as the prognosis of a high proportion of patients with global glomerulosclerotic IgAN. Results This study included 105 IgAN patients with high proportion of global glomerulosclerotic. The level of urinary protein IgG was significantly correlated with clinical prognostic factors. The level of urinary protein IgG was positively correlated with urinary protein excretion (rs = 0.834, P  
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-021-02858-y